Veniti Begins VIRTUS Trial for Its Vici Venous Stent System in the US

December 1, 2014—Veniti, Inc. announced that it has enrolled the first United States patients in the VIRTUS trial of the Veniti Vici venous stent system. The four procedures were performed at two sites, including the Heart and Vascular Center, St. Joseph Hospital in Orange, California.

Mahmood Razavi, MD, who is director for clinical trials and research, serves as coprincipal investigator for the VIRTUS trial. In the company’s press release, Dr. Razavi commented, “We are pleased to be among the first centers to treat patients using the Vici venous stent system. In treating patients with venous disease, we must address the specific challenges encountered as compared to those with arterial disease. We are excited to participate in the VIRTUS trial of a stent designed from its inception for use in the venous system.”

According to the company, the Vici venous stent system was designed to be compatible with the unique anatomy and pathophysiology of the venous system, including crush resistance, vessel coverage, and flexibility. It is intended for use in veins of the lower extremities and pelvis, including the iliac and common femoral veins, in patients who exhibit symptomatic venous outflow obstruction, which is associated with disorders of the lower extremities such as varicose veins and venous ulcers.

The Venous stent system has received CE Mark approval and is commercially available in Europe, advised Veniti.